Trials / Not Yet Recruiting
Not Yet RecruitingNCT07204080
(TNX-1500) in Kidney Transplant Recipients
Phase II Clinical Trial Evaluating the Safety and Efficacy of Fc-Modified Anti-CD154 mAB (TNX-1500) in Kidney Transplant Recipients
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 5 (estimated)
- Sponsor
- Ayman Al Jurdi, MD · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective is to investigate the safety and efficacy of TNX-1500, an FC-modified anti-CD154 mAb, in five kidney transplant recipients at 12 months.
Conditions
- Kidney Transplant
- Kidney Transplant Failure and Rejection
- Immunosuppression
- Immunosuppression After Kidney Transplantation
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TNX-1500 | This is an open-label, single-center, single-arm study to assess the safety and efficacy of TNX-1500, an Fc-modified anti-DF154 mAb in five adult kidney transplant recipients. |
| PROCEDURE | Kidney Transplant | Kidney Transplant |
Timeline
- Start date
- 2026-07-01
- Primary completion
- 2028-09-01
- Completion
- 2029-06-30
- First posted
- 2025-10-02
- Last updated
- 2026-02-25
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07204080. Inclusion in this directory is not an endorsement.